Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy

Genomic Classification of Cutaneous Melanoma

Rehan Akbani, Kadir C. Akdemir, Bülent Arman Aksoy et al. · Cell · 2015 · 3.2K citations · Full text

Dermoscopic Image, Skin Cancer, Medicine +8

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

Paul Wan, Mathew J. Garnett, S. Mark Roe et al. · Cell · 2004 · 2.8K citations · Full text

Oncogenic Mutations, Signal Transduction, Signaling Pathway +9

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al. · New England Journal of Medicine · 2014 · 2.6K citations · Full text

A Landscape of Driver Mutations in Melanoma

Eran Hodis, Ian R. Watson, Gregory V. Kryukov et al. · Cell · 2012 · 2.6K citations · Full text

Somatic Variant, Driver Mutations, Medicine +5